US 11,732,049 B2
Methods of reducing or lowering blood glucose levels in a human subject by administering an antibody that specifically binds human glucagon receptor
Wenyan Shen, Redwood City, CA (US); Yan Wang, Foster City, CA (US); Hugo Matern, San Mateo, CA (US); and Zhonghao Liu, Redwood City, CA (US)
Assigned to NGM Biopharmaceuticals, Inc., South San Francisco, CA (US)
Filed by NGM Biopharmaceuticals, Inc., South San Francisco, CA (US)
Filed on Mar. 19, 2021, as Appl. No. 17/206,910.
Application 17/206,910 is a division of application No. 15/881,493, filed on Jan. 26, 2018, granted, now 10,995,145.
Claims priority of provisional application 62/451,603, filed on Jan. 27, 2017.
Prior Publication US 2021/0332144 A1, Oct. 28, 2021
Int. Cl. C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01)
CPC C07K 16/2869 (2013.01) [A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/34 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 24 Claims
 
1. A method of reducing or lowering blood glucose levels in a human subject, the method comprising administering to the human subject a therapeutically effective amount of an antibody that specifically binds human glucagon receptor (GCGR; SEQ ID NO:223), wherein the antibody comprises: a heavy chain variable region (VH) comprising a VH complementarity determining region (CDR)1, a VH CDR2, and a VH CDR3 from the amino acid sequence of SEQ ID NO:25, and a light chain variable region (VL) comprising a VL CDR1, a VL CDR2, and a VL CDR3 from the amino acid sequence of SEQ ID NO:26.